First Presentation of Early Data for Pembrolizumab (MK-3475), Merck’s Investigational Anti-PD-1 Antibody, in Advanced Head and Neck Cancer at ASCO 2014

Dateline City:

CHICAGO

Overall Response Rate of 20 Percent for Pembrolizumab as Single Agent in Patients with Advanced Head and Neck Cancer
Merck Initiating Phase 3 Study in Advanced Head and Neck Cancer with Pembrolizumab Versus Standard of Care in Q3 2014 (KEYNOTE-040)
Additional 110 Patients with Advanced Head and Neck Cancer to be Enrolled in KEYNOTE-012 with Assessment of PD-L1 Tumor Levels Planned
Pembrolizumab Announced as New Generic Name for MK-3475

CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the first presentation of early findings from a Phase 1b
study (KEYNOTE-012) evaluating pembrolizumab (MK-3475), Merck’s
investigational anti-PD-1 antibody, as a single-agent (monotherapy) in
patients with PD-L1 positive, advanced head and neck cancer.
Language:

English

Contact:

MerckMedia Contacts:Ian McConnell, [phone]orClaire Mulhearn, [phone]orInvestor Contacts:Carol Ferguson, [phone]orJustin Holko, [phone]

Ticker Slug:

Ticker: MRK ...

Source: Merck.com - Corporate News - June 1, 2014 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news